Bioasis Technologies reports positive results from an efficacy study of its blood-brain barrier penetrant

Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) said results from an efficacy study of a blood-brain barrier penetrant interleukin-1 receptor inhibitor were successful in a preclinical rodent model of multiple sclerosis.

Connecticut-based Bioasis is a pre-clinical, research-stage biopharmaceutical company developing a proprietary xB3 platform technology for the delivery of therapeutics across the blood-brain barrier (BBB), as well as the treatment of central nervous system (CNS) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.

According to the company, a previously released work noted a recombinant fusion protein of Bioasis’ proprietary xB3 peptide with an interleukin-1 receptor antagonist (xB3-IL-1RA) demonstrated efficient delivery of effective concentrations of IL-1RA to the brain. The introduction elicited analgesia in a neuropathic pain animal model, while systemic administration of IL-1RA alone did not elicit analgesia.

READ: Bioasis Technologies appoints former PricewaterhouseCoopers veteran Dave Jenkins as CFO

As the statement noted, because IL-1 cytokines have been implicated in many autoimmune and neuroinflammatory diseases, xB3-IL-1RA was investigating disease in the rodent experimental allergic encephalomyelitis (EAE) model of multiple sclerosis. 

Multiple doses of xB3-IL-1RA were administered during the disease induction phase, resulting in both delayed onset and overall reduced clinical symptom score in animals treated with xB3-IL-1RA compared to the control group of animals. 

The data helps to further evidence the utility of xB3 peptide as a platform technology for the delivery of large molecule biologics across the BBB. Additionally, the study affirms the potential applicability of xB3-IL-1RA in the treatment of neuroinflammatory diseases such as multiple sclerosis.

“[The] data further confirm the ability of the xB3 delivery platform to enhance the delivery of large molecule therapeutics into CNS compartments with demonstrated disease-relevant efficacy,” Dr Deborah Rathjen, executive chair of the Bioasis said in the press release. “We are progressing these data and believe that xB3-IL-1RA holds promise for the treatment of a broad range of neuroinflammatory diseases.”

Contact the writer at [email protected]

Follow her on Twitter @MissInformd

Story by ProactiveInvestors